Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
EV is approved alone and with pembrolizumab (EV/P) for aUC. EV-related dermatologic events (EVDEs) have been correlated with improved outcomes. We identified novel pre- and on-treatment autoantibodies in sera of patients with mUC treated with EV or EV/P which correlated with EVDEs.
Authors
- Noah M. Hahn (ORCID: https://orcid.org/0000-0002-1016-9024)
- Livia Casciola‐Rosen (ORCID: https://orcid.org/0000-0002-4172-1539)
- Antony Rosen (ORCID: https://orcid.org/0000-0002-8374-4763)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Burles A. Johnson (ORCID: https://orcid.org/0000-0002-7180-8790)
- David J. McConkey (ORCID: https://orcid.org/0000-0003-1971-0638)
- Evangelia Vlachou (ORCID: https://orcid.org/0009-0007-5486-2983)
- Stephanie Russell
- Yuezhou Jing (ORCID: https://orcid.org/0000-0002-4597-7064)
- Daniel Stairiker
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Rochester Medical Center (US)
- Sibley Memorial Hospital (US)
- Johns Hopkins Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0039
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Johns Hopkins University